Article: Curis Seeking BMP Partner As Ortho Biotech Backs Out.

West Coast Editor

Curis Inc.'s bone morphogenetic protein-7 for kidney disease could move along more quickly with another partner, now that longstanding licensee Ortho Biotech Products L.P. has terminated the deal. But all work on the compound is still preclinical, and Curis has just begun contacting potential collaborators.

In late 2002, Curis licensed the technology to the subsidiary of New Brunswick, N.J.-based Johnson & Johnson, centered on BMP-7, for all indications except repair or regeneration of local musculoskeletal tissue defects and dental defects, which are covered under a separate deal with Stryker Corp., of Kalamazoo, Mich. (See BioWorld ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!